Roche
Roche, officially known as F. Hoffmann-La Roche Ltd, is a global leader in the pharmaceutical and diagnostics industry, headquartered in Basel, Switzerland (CH). Founded in 1896, Roche has established itself as a pioneer in innovative healthcare solutions, focusing on areas such as oncology, immunology, infectious diseases, and personalised medicine. With a strong presence in Europe, North America, and Asia, Roche is renowned for its cutting-edge products, including biologics and molecular diagnostics, which set it apart in the competitive landscape. The company has achieved significant milestones, including the development of groundbreaking therapies and diagnostic tools that enhance patient outcomes. Roche's commitment to research and development has solidified its position as a top player in the global healthcare market, consistently ranking among the largest pharmaceutical companies worldwide.
DitchCarbon Score
How does Roche's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Roche's score of 77 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Roche's reported carbon emissions
In 2023, Roche reported total carbon emissions of approximately 6,000,000,000 kg CO2e globally, with emissions distributed across various scopes: 240,266,000 kg CO2e for Scope 1, 98,480,000 kg CO2e for Scope 2, and about 5,978,508,000 kg CO2e for Scope 3. The company has set ambitious climate commitments, aiming for a 42% reduction in Scope 1 and 2 emissions and a 25% reduction in Scope 3 emissions by 2030, compared to 2022 levels. Furthermore, Roche is committed to achieving net zero emissions across its entire value chain by 2045. These targets align with the Science Based Targets initiative (SBTi), reinforcing Roche's dedication to sustainable practices within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 249,350,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 114,452,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 6,402,719,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Roche is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
